Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 84 publications

Cholangiocarcinoma - Morphology, Immunohistochemistry, and Genetics.

Cholangiocarcinoma - Morphology, Immunohistochemistry, and Genetics.

Journal: Ceskoslovenska patologie
Published: October 16, 2025

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation.

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation.

Journal: The oncologist
Published: August 18, 2025

Sequential Fibroblast Growth Factor Receptor Inhibition in Intrahepatic Cholangiocarcinoma: Navigating an Evolving Landscape of Resistance and Opportunity-A Case Report and Current Opinion.

Sequential Fibroblast Growth Factor Receptor Inhibition in Intrahepatic Cholangiocarcinoma: Navigating an Evolving Landscape of Resistance and Opportunity-A Case Report and Current Opinion.

Journal: Oncology and therapy
Published: June 16, 2025

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update.

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update.

Journal: Pharmacological research
Published: May 27, 2025

Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review.

Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review.

Journal: Oncology and therapy
Published: May 23, 2025

Pharmacologic features, clinical applications, and drug safety evaluation of futibatinib in the treatment of biliary tract cancer (BTC).

Pharmacologic features, clinical applications, and drug safety evaluation of futibatinib in the treatment of biliary tract cancer (BTC).

Journal: Expert opinion on drug safety
Published: May 01, 2025

A case of FGFR2 fusion-positive pancreatic head tumor with difficult differential diagnosis between cholangiocarcinoma and pancreatic ductal adenocarcinoma.

A case of FGFR2 fusion-positive pancreatic head tumor with difficult differential diagnosis between cholangiocarcinoma and pancreatic ductal adenocarcinoma.

Journal: Clinical journal of gastroenterology
Published: April 08, 2025

Data mining and safety analysis of FGFR tyrosine kinase inhibitors based on the FAERS database.

Data mining and safety analysis of FGFR tyrosine kinase inhibitors based on the FAERS database.

Journal: Scientific reports
Published: March 11, 2025

Fibroblast growth factor therapies in biliary tract cancers: current and future state.

Fibroblast growth factor therapies in biliary tract cancers: current and future state.

Journal: Expert opinion on investigational drugs
Published: December 04, 2024

Practical Management of Adverse Events Associated With FGFR Inhibitors for Cholangiocarcinoma for the Advanced Practice Provider.

Practical Management of Adverse Events Associated With FGFR Inhibitors for Cholangiocarcinoma for the Advanced Practice Provider.

Journal: Journal of the advanced practitioner in oncology
Published: November 20, 2024

Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.

Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.

Journal: European journal of cancer (Oxford, England : 1990)
Published: October 29, 2024

Plain language summary: an analysis of the safety of futibatinib treatment in people with different types of cancer.

Plain language summary: an analysis of the safety of futibatinib treatment in people with different types of cancer.

Journal: Future oncology (London, England)
Published: October 28, 2024
Showing 1-12 of 84

Last Updated: 10/31/2025